events
30 November 2018
Da Volterra at J.P. Morgan Healthcare Conference in SFO!
Meet Florence Séjourné, CEO of Da Volterra, at J.P. Morgan Healthcare Conference, the largest and most informative Healthcare Investment Symposium…
The US Patent and Trademark Office has recently granted a new patent for Da Volterra in the USA. The patent was issued under number 10,052,288 and relates to DAV132, our phase 2 asset to protect the intestinal microbiota from antibiotic-induced disruption.
This new patent reinforces our intellectual property portfolio and comes as a complement to the already 100+ patents protecting our products worldwide.
